RxDoctor Payments DataLook up a doctor →

Lakshminarayanan Nandagopal

Hematology & Oncology · Fredericksburg, VANPI 1770897548

Payments from drug & device makers

$3,904,156in general payments, 2019–2025

Across 697 payments — averaging $5601.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medivation LLC.$1.1M
  • AbbVie$1M
  • AstraZeneca$517K
  • Merck$437K
  • Aadi Bioscience, Inc.$381K
  • Amgen$181K
  • plus $219K from 54 others

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medivation LLC.32$1,123,438
AbbVie54$1,046,343
AstraZeneca(2 entities)34$517,147
Merck49$436,542
Aadi Bioscience, Inc.10$380,813
Amgen17$180,500
Pfizer117$157,180
Seagen Inc.7$31,584
Biontech SE10$19,898
E.r. Squibb & Sons, L.L.C.15$1,679
Organon1$1,500
Novartis49$1,034
Johnson & Johnson(2 entities)35$722
Incyte Corporation25$513
Daiichi Sankyo Inc.21$442
Bayer15$353
Astellas Pharma US Inc13$276
Gilead(2 entities)11$261
EMD Serono, Inc.13$247
Bristol Myers Squibb10$200
Takeda Pharmaceuticals U.S.A., Inc.8$197
Sanofi7$193
Genentech USA, Inc.8$181
GSK8$174
Regeneron Healthcare Solutions, Inc.6$173
Servier Pharmaceuticals LLC8$163
Karyopharm Therapeutics Inc.6$136
Lilly USA, LLC7$131
Taiho Oncology, Inc.5$129
Eisai Inc.6$120
Pharmaessentia USA Corporation5$115
Dendreon Pharmaceuticals LLC5$111
Stemline Therapeutics Inc.3$107
Pharmacosmos Therapeutics Inc.5$106
Array Biopharma Inc8$103
Mirati Therapeutics, Inc.4$100
Adaptive Biotechnologies Corporation4$87
Pharmacyclics LLC, An Abbvie Company4$83
Geron Corporation3$77
Sobi, Inc3$71
Beigene USA, Inc.3$69
Tersera Therapeutics LLC4$65
Boehringer Ingelheim3$62
Genentech, Inc.1$57
Alnylam Pharmaceuticals Inc.3$55
ADC Therapeutics America, Inc.3$52
Exelixis Inc.2$50
Coherus Oncology, Inc.2$44
Spectrum Pharmaceuticals Inc.2$44
Deciphera Pharmaceuticals Inc.2$37
Morphosys, US Inc.2$36
Heron Therapeutics, Inc.2$30
Puma Biotechnology, Inc.2$29
Tempus AI, Inc1$29
Immunogen, Inc.1$28
Blue Earth Diagnostics1$26
Genmab U.S., Inc.1$23
Menarini Silicon Biosystems, Inc.1$22
Beone Medicines USA, Inc.1$20
Rigel Pharmaceuticals, Inc.1$20

How this compares

$3,904,156 in reported general payments places this provider in the 95th percentile of 293 hematology & oncology providers in Virginia.

See all hematology & oncology providers in Virginia →

Medicare billing

Part B allowed, 2024
$308,301
Medicare patients
475
Services billed
11,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Fredericksburg

See the full list for Virginia →

Where these figures come from

Is this you, or does something look wrong? →